Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival; however, relapses are common. A number of receptor tyrosine kinases (RTKs) including EGFR and MET have been reported to be involved in CMM metastasis and in the development of resistance to therapy, ta...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Death Dis
Hlavní autoři: Das, Ishani, Wilhelm, Margareta, Höiom, Veronica, Franco Marquez, Rodolfo, Costa Svedman, Fernanda, Hansson, Johan, Tuominen, Rainer, Egyhàzi Brage, Suzanne
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737096/
https://ncbi.nlm.nih.gov/pubmed/31506424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-019-1875-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky